Children’s Minnesota has backed the first close of 4Bio Ventures II, a $150m venture fund that will focus on areas such as cell and gene therapy.

UK-based investment firm 4Bio Capital achieved a first close of $50m for its second venture capital fund on Monday with a commitment from paediatric healthcare provider Children’s Minnesota. The other limited partners in 4Bio Ventures II have not been identified. 4Bio Capital is targeting a $150m final close by the second half of 2020. 4Bio…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.